📗 Cite This Artifact
ALS-FTD-Parkinsonism Comparison Matrix
ALS-FTD-Parkinsonism Comparison Matrix
Overview
The ALS-FTD-Parkinsonism spectrum represents a continuum of neurodegenerative disorders characterized by overlapping clinical, genetic, and pathological features. This comparison matrix systematically analyzes the shared mechanisms, genetic architecture, and therapeutic targets across [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis), [Frontotemporal Dementia (FTD) – especially the FTD-ALS spectrum](/diseases/ftd-als-spectrum), and atypical parkinsonian syndromes including [Progressive Supranuclear Palsy (PSP) – especially the corticobasal syndrome (CBS) overlap](/diseases/psp-cbd-overlap), [Corticobasal Syndrome (CBS/CBD) ](/diseases/corticobasal-syndrome), and [Multiple System Atrophy (MSA) ](/diseases/multiple-system-atrophy).
These disorders share fundamental pathogenic mechanisms including protein aggregation (TDP-43, tau, alpha-synuclein), RNA metabolism defects, nucleocytoplasmic transport dysfunction, mitochondrial dysfunction, and neuroinflammation. Understanding these shared pathways is critical for developing cross-disease therapeutic strategies and biomarkers.
Clinical Overlap Matrix
...
ALS-FTD-Parkinsonism Comparison Matrix
Overview
The ALS-FTD-Parkinsonism spectrum represents a continuum of neurodegenerative disorders characterized by overlapping clinical, genetic, and pathological features. This comparison matrix systematically analyzes the shared mechanisms, genetic architecture, and therapeutic targets across [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis), [Frontotemporal Dementia (FTD) – especially the FTD-ALS spectrum](/diseases/ftd-als-spectrum), and atypical parkinsonian syndromes including [Progressive Supranuclear Palsy (PSP) – especially the corticobasal syndrome (CBS) overlap](/diseases/psp-cbd-overlap), [Corticobasal Syndrome (CBS/CBD) ](/diseases/corticobasal-syndrome), and [Multiple System Atrophy (MSA) ](/diseases/multiple-system-atrophy).
These disorders share fundamental pathogenic mechanisms including protein aggregation (TDP-43, tau, alpha-synuclein), RNA metabolism defects, nucleocytoplasmic transport dysfunction, mitochondrial dysfunction, and neuroinflammation. Understanding these shared pathways is critical for developing cross-disease therapeutic strategies and biomarkers.
Clinical Overlap Matrix
| Clinical Feature | ALS | FTD (bvFTD) | PSP | CBS/CBD | MSA |
|-----------------|-----|-------------|-----|---------|-----|
| Motor Neuron Disease | Core (100%) | Occasional (15%) | Rare | Rare | Rare |
| Behavioral Changes | Moderate (30%) | Core (100%) | Moderate (40%) | Moderate (50%) | Mild (20%) |
| Cognitive Decline | Variable (50%) | Core (100%) | Moderate (50%) | Moderate (60%) | Moderate (40%) |
| Parkinsonism | Rare | Rare | Core (100%) | Core (100%) | Core (100%) |
| Ocular Motor Deficit | Rare | Rare | Core (70%) | Variable | Variable |
| Dystonia | Occasional | Rare | Common (60%) | Core (70%) | Variable |
| Myoclonus | Occasional | Rare | Variable | Common (50%) | Rare |
| Ataxia | Rare | Rare | Variable | Variable | Core (60%) |
| Dysphagia | Core (90%) | Variable | Common (60%) | Common (50%) | Common (70%) |
| Urinary Dysfunction | Rare | Rare | Variable | Variable | Core (80%) |
Genetic Architecture
Shared Genetic Risk Factors
The ALS-FTD-Parkinsonism spectrum shows significant genetic overlap, with several genes implicated across multiple conditions[@boylan2023][@goldman2023]:
| Gene | Protein | ALS | FTD | PSP | CBS | MSA | Key Mechanism |
|------|---------|-----|-----|-----|-----|-----|---------------|
| [C9orf72](/genes/c9orf72) | C9orf72 protein | +++ | +++ | + | + | + | RNA foci, DPR toxicity |
| [TARDBP](/genes/tardbp) | TDP-43 | +++ | ++ | - | + | - | RNA metabolism |
| [FUS](/genes/fus) | FUS protein | ++ | + | - | - | - | RNA binding |
| [GRN](/genes/grn) | Progranulin | + | +++ | + | ++ | - | Lysosomal function |
| [MAPT](/genes/mapt) | Tau | + | +++ | +++ | +++ | - | Microtubule stability |
| TBK1 | TANK-binding kinase 1 | ++ | ++ | - | + | - | Autophagy, inflammation |
| VCP | Valosin-containing protein | + | ++ | - | + | - | Protein quality control |
| SQSTM1 | p62 | + | + | + | + | - | Autophagy, signaling |
| ALS2 | Alsin | + | - | - | - | - | Endosomal trafficking |
| SETX | Senataxin | + | - | - | - | - | RNA processing |
| ATXN2 | Ataxin-2 | ++ | + | - | - | - | RNA binding, translation |
C9orf72 Hexanucleotide Repeat Expansion
The [C9orf72 repeat expansion](/mechanisms/c9orf72-hexanucleotide-repeat-expansion) is the most significant genetic link across this spectrum[@renton2011][@majounie2012]:
- ALS: 30-40% of familial, 5-10% of sporadic cases
- FTD: 20-30% of familial bvFTD
- Parkinsonism: 3-5% of cases, especially with dementia
- CBS: 5-10% of cases
- Mechanisms:
TDP-43 Proteinopathy Genes
The TDP-43 proteinopathy defines most ALS and a majority of FTD cases[@ling2013][@gabery2022]:
TDP-43 Pathology Classification:
├── ALS: ~95% of cases (sporadic and most familial)
│ └── Type B pattern (skeletal muscle, motor neurons)
├── FTD: ~50% of cases (FTLD-TDP)
│ ├── Type A (GRN mutations): Neuronal perikarya, dystrophic neurites
│ ├── Type B (C9orf72): Moderate perikarya, few neurites
│ └── Type C (Semantic variant PPA): Long dystrophic neurites
├── CBS: ~30% of cases (usually FTLD-TDP type A)
└── PSP: Rare (~10% of cases)
Pathological Mechanisms Comparison
Protein Aggregation Patterns
| Protein | ALS | FTD | PSP | CBS | MSA | Notes |
|---------|-----|-----|-----|-----|-----|-------|
| TDP-43 | +++ | +++ | + | ++ | - | Most common aggregate |
| Tau (3R) | - | + | - | + | - | Pick bodies |
| Tau (4R) | - | + | +++ | +++ | - | PSP, CBD signature |
| α-Synuclein | + | + | + | + | +++ | MSA, incidental |
| FUS | ++ | + | - | - | - | ALS-FUS cases |
Shared Molecular Mechanisms
1. RNA Metabolism Dysregulation
RNA metabolism defects are central to ALS-FTD pathogenesis[@meyer2023]:
- TDP-43 loss-of-function: Aberrant splicing of thousands of neuronal transcripts
- FUS mutations: Disrupted RNA transport and splicing
- C9orf72: RNA foci sequester essential RBPs
- RBP aggregation: Stress granule dynamics altered
RNA Metabolism Defects:
├── Pre-mRNA splicing abnormalities
├── mRNA transport deficits
├── MicroRNA dysregulation
├── Stress granule formation
└── Translation control impairment
2. Nucleocytoplasmic Transport Dysfunction
Defects in nuclear import/export are emerging as a key shared mechanism[@zhang2023]:
- C9orf72 DPRs: Disrupt nuclear pore integrity
- TDP-43 mislocalization: Loss of nuclear function
- Importin/Exportin dysregulation: Altered nuclear transport proteins
- Nuclear pore stress: Compromessed barrier function
Nucleocytoplasmic Transport Defects:
├── Nuclear pore complex stress
├── Importin-α/β dysfunction
├── CRM1/exportin dysfunction
├── TDP-43 nuclear import loss
└── RNA export impairment
3. Mitochondrial Dysfunction
Energy metabolism impairment is common across the spectrum:
- Complex I deficiency: Prominent in ALS, PD
- Calcium homeostasis: Altered in CBS, PSP
- ATP production: Reduced across all conditions
- Oxidative stress: Elevated ROS production
- Mitochondrial dynamics: Impaired fission/fusion
4. Neuroinflammation
Microglial activation and innate immune responses are prominent[@gao2022][@wu2022]:
- TREM2 variants: Increase risk across ALS, FTD, AD
- Complement activation: C1q, C3 involvement
- Cytokine elevation: IL-6, TNF-α, IL-1β
- Astrocyte reactivity: A1 phenotype in ALS-FTD
- Autoimmune components: Shared epitopes, cross-reactivity
Neuroinflammation Across Spectrum:
├── Microglial activation (prominent in ALS, FTD)
├── Complement system activation
├── Pro-inflammatory cytokine elevation
├── TREM2 dysfunction
└── Astrocyte reactivity (A1 phenotype)
Autophagy-Lysosomal Pathway
Dysfunction in protein clearance mechanisms is shared:
| Component | ALS | FTD | PSP | CBS | MSA |
|-----------|-----|-----|-----|-----|-----|
| Autophagy | ++ | ++ | ++ | ++ | +++ |
| Ubiquitin-proteasome | ++ | ++ | + | + | + |
| Lysosomal function | + | +++ | + | ++ | +++ |
| VCP mutations | + | ++ | - | + | - |
| GRN haploinsufficiency | + | +++ | - | ++ | - |
Neuroimaging Biomarkers Comparison
Structural MRI Findings
| Finding | ALS | FTD | PSP | CBS | MSA |
|---------|-----|-----|-----|-----|-----|
| Motor cortex atrophy | +++ | + | + | ++ | + |
| Frontotemporal atrophy | + | +++ | + | ++ | - |
| Midbrain atrophy | - | - | +++ | + | ++ |
| Brainstem atrophy | + | - | ++ | + | ++ |
| Cerebellar atrophy | - | - | + | + | +++ |
| Pons atrophy | - | - | ++ | - | +++ |
| Asymmetric findings | ++ | + | - | +++ | - |
Advanced Imaging Biomarkers
| Technique | ALS | FTD | PSP | CBS | MSA |
|-----------|-----|-----|-----|-----|-----|
| DTI: Corticospinal tract | +++ | + | ++ | ++ | + |
| DTI: Frontotemporal WM | + | +++ | + | ++ | - |
| RS-fMRI: Motor network | ++ | + | ++ | +++ | + |
| RS-fMRI: Salience network | + | +++ | + | ++ | - |
| FDG-PET: Hypometabolism | Motor cortex | Frontal | Midbrain, frontal | Asymmetric | Cerebellar, brainstem |
Fluid Biomarkers
| Biomarker | ALS | FTD | PSP | CBS | MSA | Utility |
|-----------|-----|-----|-----|-----|-----|---------|
| NfL | +++ | ++ | ++ | ++ | ++ | Disease progression |
| pNfH | +++ | + | ++ | ++ | + | Specificity |
| TDP-43 (CSF) | ++ | ++ | - | + | - | Disease activity |
| Total tau | + | + | +++ | ++ | + | PSP/CBS specificity |
| p-tau181 | + | + | ++ | ++ | - | Differential |
| α-Synuclein (SAA) | - | - | - | - | +++ | MSA diagnosis |
| Neurofilament light | +++ | ++ | ++ | ++ | ++ | Prognosis |
| Progranulin (plasma) | + | +++ | - | ++ | - | GRN carriers |
Therapeutic Target Overlap
Shared Therapeutic Targets
| Target | ALS | FTD | PSP | CBS | MSA | Therapeutic Approach |
|--------|-----|-----|-----|-----|-----|---------------------|
| RNA metabolism | +++ | +++ | + | + | - | ASOs, small molecules |
| Nucleocytoplasmic transport | ++ | ++ | + | + | - | Nuclear pore modulators |
| TDP-43 aggregation | +++ | +++ | + | ++ | - | Immunotherapy, ASOs |
| Tau pathology | - | + | +++ | +++ | - | Antibodies, inhibitors |
| Neuroinflammation | +++ | +++ | +++ | +++ | ++ | TREM2 agonists, anti-cytokines |
| Mitochondrial function | +++ | ++ | ++ | ++ | ++ | Antioxidants, modulators |
| Autophagy enhancement | ++ | ++ | ++ | ++ | +++ | Autophagy inducers |
| Neurotrophic support | ++ | ++ | + | + | + | Growth factors |
Clinical Trial Landscape
| Therapy | Target | ALS | FTD | PSP | CBS | Stage |
|---------|--------|-----|-----|-----|-----|-------|
| Tofersen | SOD1 | FDA approved | - | - | - | Approved |
| Lecanemab | Aβ | - | - | - | - | FDA approved (AD) |
| Tilavonemab | Tau | - | - | Phase 2 | Phase 2 | Active |
| Cinpanemab | α-Syn | - | - | - | - | Phase 2 |
| Rapamycin | mTOR/autophagy | Phase 2 | Phase 2 | Phase 2 | Phase 2 | Active |
| Gene therapy (C9orf72) | C9orf72 | Phase 1/2 | Phase 1/2 | Preclinical | - | Developing |
| Gene therapy (GRN) | Progranulin | - | Phase 1/2 | - | Preclinical | Developing |
Drug Repositioning Opportunities
| Drug | Original Indication | Potential Use | Mechanism |
|------|---------------------|---------------|-----------|
| Riluzole | ALS | FTD, PSP | Glutamate modulation |
| Edaravone | ALS | FTD, CBS | Antioxidant |
| Minocycline | Antibiotic | ALS, FTD | Anti-inflammatory |
| Arimoclomol | HD | ALS | HSP induction |
| Sodium phenylbutyrate | Urea cycle | ALS | ER stress reduction |
| Amantadine | Parkinson's | PSP, CBS | Dopaminergic |
Disease Progression Comparison
| Parameter | ALS | FTD | PSP | CBS | MSA |
|-----------|-----|-----|-----|-----|-----|
| Mean onset age | 55-65 | 50-60 | 60-70 | 60-70 | 50-60 |
| Median survival | 2-4 years | 6-11 years | 5-7 years | 5-8 years | 6-9 years |
| Progression rate | Fast | Variable | Moderate | Variable | Slow-moderate |
| Primary cause of death | Respiratory failure | Complications | Falls, complications | Complications | Respiratory, autonomic |
Prognostic Factors
ALS:
- Bulbar onset = worse prognosis
- Age >60 = shorter survival
- Rapid progression = shorter survival
- ALS overlap = shorter survival
- Early behavioral disinhibition = faster progression
- Richardson's syndrome = typical progression
- CBS phenotype = variable
- Cerebellar type = faster progression
- Autonomic failure early = shorter survival
Cross-Disease Connections
ALS-FTD Connection
The [FTD-ALS spectrum](/diseases/ftd-als-spectrum) represents the strongest clinical and genetic overlap[@hardiman2017]:
- 15% of ALS patients meet FTD criteria
- 50% of ALS show subclinical cognitive changes
- Shared TDP-43 pathology (95% ALS, 50% FTD)
- C9orf72 is the major shared gene
ALS-Parkinsonism Connection
- Parkinsonism in ALS: 1-5% of cases
- ALS in Parkinsonism: Rare but documented
- C9orf72 expansion: Found in 3-5% of PD with dementia
- SOD1 mutations: Rare parkinsonian features
FTD-Parkinsonism Connection
The [PSP-CBD overlap](/diseases/psp-cbd-overlap) is well-established[@sieben2012]:
- Shared 4R tau pathology
- Overlapping clinical phenotypes
- Common genetic factors (MAPT, GRN)
- Similar therapeutic approaches
MSA-ALS Connection
- Overlap is rare but documented
- Shared alpha-synuclein pathology in some cases
- Possible TDP-43 co-pathology
- Autonomic dysfunction distinguishes MSA
Research Directions
Biomarker Development
Priority areas for cross-disease biomarkers:
- Blood NfL: Universal disease progression marker
- p-tau217: Differential diagnosis (AD vs FTD vs PSP)
- TDP-43 seeds: Disease-specific detection
- Genetic panels: Comprehensive screening
Therapeutic Development
Strategic approaches:
- Repurposing: Existing drugs across indications
- Gene-specific: ASOs for C9orf72, SOD1, GRN
- Shared mechanisms: RNA metabolism, neuroinflammation
- Combination therapy: Multi-target approaches
Clinical Trial Design
Recommendations:
- Platform trials: Multi-arm, multi-disease
- Biomarker enrichment: Genetic stratification
- Composite endpoints: Cross-disease measures
- Real-world evidence: Natural history studies
See Also
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [FTD-ALS Spectrum](/diseases/ftd-als-spectrum)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
- [Parkinson Plus Syndromes](/diseases/parkinson-plus-syndromes)
- [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [C9orf72 Gene](/genes/c9orf72)
- [TARDBP Gene](/genes/tardbp)
- [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
External Links
- [ALS Association](https://www.alsassociation.org/)
- [The Frontotemporal Dementia Research Groups](https://www.ftdrg.org/)
- [CurePSP Foundation](https://www.psp.org/)
- [MSA Coalition](://www.msacoalition.org/)
- [PubMed: ALS-FTD Spectrum](https://pubmed.ncbi.nlm.nih.gov/?term=ALS+FTD+spectrum)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | diseases-als-ftd-parkinsonism-comparison |
| kg_node_id | None |
| entity_type | disease |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-bc30cc49dc59 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-als-ftd-parkinsonism-comparison'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-diseases-als-ftd-parkinsonism-comparison?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[ALS-FTD-Parkinsonism Comparison Matrix](http://scidex.ai/artifact/wiki-diseases-als-ftd-parkinsonism-comparison)
http://scidex.ai/artifact/wiki-diseases-als-ftd-parkinsonism-comparison